Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study

Condition:   Intrahepatic Cholangiocarcinoma Interventions:   Drug: Camrelizumab;   Drug: Apatinib Sponsors:   Sun Yat-sen University;   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials